Abstract | BACKGROUND: METHODS: All prevalent patients from the dialysis unit of the Hospital Italiano de Buenos Aires as of 1 June 2015 were evaluated. They were on three times per week bicarbonate/ citrate-buffered HD. They were not receiving phosphate binders or magnesium-containing drugs. The average of three successive monthly magnesium serum levels was considered as the baseline magnesium concentration. Sevelamer carbonate use was retrieved from the patient's clinical records. RESULTS: One hundred and fifty-one patients were included. A large proportion of individuals were on proton pump inhibitors (PPIs) (66%) and more than 50% were using sevelamer carbonate. Serum magnesium levels were significantly higher in those receiving sevelamer compared with those who did not (2.05 ± 0.3 versus 1.8 ± 0.4 mg/dL; P < 0.05). A larger proportion of individuals receiving sevelamer were among those with normal serum magnesium (P = 0.02), while among those with hypomagnesemia, a larger proportion were on PPIs. In the multivariate model including the use of PPIs, sevelamer carbonate resulted in an independent protective factor for hypomagnesemia (odds ratio: 0.44; 95% confidence interval: 0.21-0.87). CONCLUSIONS:
|
Authors | Guillermo Rosa-Diez, Armando Luis Negri, Maria Soledad Crucelegui, Romina Philippi, Hernán Perez-Teysseyre, Carmen Sarabia-Reyes, Henry Loor-Navarrete, Ricardo Heguilen |
Journal | Clinical kidney journal
(Clin Kidney J)
Vol. 9
Issue 3
Pg. 481-5
(Jun 2016)
ISSN: 2048-8505 [Print] England |
PMID | 27274837
(Publication Type: Journal Article)
|